ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Triple Negative Breast Cancer
Breast Cancer

Ovarian Cancer trials near Indianapolis, IN, USA:

Locations recently updated

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 213 other locations

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Phase 3

Genelux

Indianapolis, Indiana, United States and 22 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 176 other locations

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 3

Mural Oncology

Indianapolis, Indiana, United States and 117 other locations

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high fola...

Enrolling
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Bevacizumab
Drug: Mirvetuximab soravtansine plus Bevacizumab

Phase 3

ImmunoGen
ImmunoGen

Indianapolis, Indiana, United States and 151 other locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Indianapolis, Indiana, United States and 207 other locations

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...

Active, not recruiting
Ovarian Neoplasms
Drug: Placebo
Drug: Niraparib

Phase 3

Tesaro
Tesaro

Indianapolis, Indiana, United States and 194 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Rucaparib

Phase 3

pharmaand

Indianapolis, Indiana, United States and 237 other locations

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,...

Active, not recruiting
Carcinoma, Ovarian Epithelial
Ovarian Cancer
Drug: Bevacizumab
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Indianapolis, Indiana, United States and 186 other locations

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Fallopian Tube Cancer
Ovarian Cancer
Drug: Docetaxel
Drug: Placebo for olaparib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Indianapolis, Indiana, United States and 226 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems